Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Treatment with Adalimumab for adult patients with JIA is recommended in Lancashire and South Cumbria in the following circumstances:
- Young people with JIA currently being treated with one of the agents and transferring over from adolescent to adult services
- Patients with JIA whose disease becomes active during adult life
- Patients with JIA requiring a biologic agent to be reinstated (e.g. after a period of remission or pregnancy)
In the above circumstances treatment is only recommended if the following criteria are met:
- Treatment was in line with NICE TA238 or TA373 before transfer to adult services OR is in line with NICE TA238 or TA373 (with the exception of any age restrictions) for newly treated patients. For continuation into adulthood, if treatment was not in line with a NICE TA, the patient may continue to receive treatment until the prescribing clinician feels this may be stopped.
Reason for decision: